Search Results for: DNA VACCINES MARKET DNA Vaccines
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
Global Market for DNA Vaccines to Reach $2.7 Billion August 25, 2014The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...
Global Market for DNA Vaccines to Reach $2.7 Billion August 21, 2014The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...
PROTEIN THERAPEUTICS MARKET – Technology Advances Spur Market Growth of Protein Therapies November 7, 2016
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.
NIH Using PharmaJet in DNA Vaccine Clinical Trial August 10, 2016PharmaJet recently announced that the National Institutes of Health will use the PharmaJet Stratis needle-free device in a DNA vaccine...
SINGLE-USE MARKET – Rise of Single-Use Technologies & Systems in Biopharmaceuticals November 19, 2015
Kevin James and Shalini S. Dewan of BCC Research believe eliminating the risk of contamination is the greatest challenge faced by manufacturers of biopharmaceuticals, and currently, this requires high-level monitoring of critical manufacturing processes. Single-use technology aids biopharmaceutical manufacturers in overcoming this challenge by reducing or eliminating the need for sterilization between batches, thereby improving operational efficiency.
DNA VACCINE TECHNOLOGY – A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs August 31, 2015
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
Paragon Bioservices to be Acquired for $1.2 Billion April 15, 2019
Catalent, Inc. and Paragon Bioservices, Inc. and Catalent Inc. recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.
Luke S. Gill, MSc, MBA, believes understanding and overcoming various challenges in the development of immunotherapeutic agents will be critical to clinical trial success and, ultimately, market approval.
Inovio Enters License & Collaboration Agreement With ApolloBio January 8, 2018Inovio Pharmaceuticals, Inc. recently announced it entered an amended agreement providing ApolloBio Corporation with the exclusive right to develop and...
SPECIAL FEATURE – Platform Technologies: Not Just for Big Pharma October 3, 2016
Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.
David Enloe, Althea’s President and CEO, discusses his company’s business strategy, why companies choose Althea, trends in the CMO industry, and how the company is growing since the acquisition of Ajinomoto.